SECsense Logo

Alterity Therapeutics 2025 SEC Form 6-K: A$40M Raised for MSA Drug Development

$ATHE
Form 6-K
Filed on: 2025-02-10
Source
Alterity Therapeutics 2025 SEC Form 6-K: A$40M Raised for MSA Drug Development

Here are the key insights from the financial report (SEC Form 6-K) for Alterity Therapeutics Limited:

  1. Filing Type and Date:
  • This is an SEC Form 6-K, indicating a report by a foreign private issuer.
  • The filing is dated February 10, 2025.
  1. Company Information:
  • Name: Alterity Therapeutics Limited.
  • Address: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
  • The company is identified as a development stage enterprise.
  1. Securities Registration:
  • The report indicates that it is being incorporated by reference into various registration statements:
    • Form S-8 (Registration of Securities under the Securities Act).
    • Form F-3 (Registration of Securities of Foreign Private Issuers).
  • Specific registration numbers mentioned are 333-251073, 333-248980, 333-228671, 333-274816, 333-251647, 333-231417, and 333-250076.
  1. Financial Activity:
  • Alterity Therapeutics has raised A$40 million to advance the development of its drug candidate ATH434, which is specifically targeted for Multiple System Atrophy (MSA).
  1. Signature:
  • The report is signed by Geoffrey P. Kempler, who is the Chairman of the company.
  1. Indication of Filing:
  • The registrant indicates that it will file annual reports under Form 20-F, suggesting compliance with international financial reporting standards.

These points summarize the critical financial activities and structural information regarding Alterity Therapeutics as of the specified date. The mention of raising substantial funds for drug development highlights the company's ongoing efforts in the biotech sector.